As of November 6, 2026, ARS Pharmaceuticals, Inc. is a publicly traded company (Nasdaq: SPRY). The largest holder reporting an active stake on Schedule 13D is RA Capital, at 11.1%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Passive holders reporting on Schedule 13G include Rubric Capital Management LP (8.06%), BlackRock (5.3%) (Schedule 13D/A, October 1, 2025).
Is this your company?
About to sign with, pay or invest in ARS Pharmaceuticals, Inc.? See the free Snapshot first.
Free to see. No signup.
Is ARS Pharmaceuticals, Inc. a real, registered company?
- ARS Pharmaceuticals, Inc. files with the SEC under CIK 1671858 (its SEC filings).
- Its shares are listed under the ticker SPRY on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in San Diego, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under ARS Pharmaceuticals, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Richard Lowenthal, Director (Form 8-K filed 2026-07-17). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names BlackRock (filed 2026-07-27).
Who are ARS Pharmaceuticals, Inc.'s owners and officers?
ARS Pharmaceuticals, Inc.: incorporated in Delaware; business address in San Diego, California; industry Pharmaceutical Preparations (Schedule 13G, 2026-07-27).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-07-27 | Blackrock, Inc. | 5.3% |
| Schedule 13G/A, 2026-07-14 | Millennium Management LLC | 2.5% |
| Schedule 13G/A, 2026-05-15 | Rubric Capital Management LP | 8.06% |
| Schedule 13G/A, 2026-04-27 | Blackrock, Inc. | 4.98% |
| Schedule 13G/A, 2026-03-31 | Millennium Management LLC | 6% |
| Schedule 13G, 2026-03-24 | Millennium Management LLC | 5.4% |
| Schedule 13G, 2026-02-13 | Rubric Capital Management LP | 6.27% |
| Schedule 13G, 2026-01-21 | Blackrock, Inc. | 5.1% |
| Schedule 13D/A, 2025-10-01 | Ra Capital Management, L.P. | 11.1% |
| Schedule 13D/A, 2025-08-01 | James E. Flynn | 7.75% |
| Schedule 13D/A, 2025-07-22 | James E. Flynn | 8.79% |
| Schedule 13D/A, 2025-07-02 | James E. Flynn | 9.9% |
Questions about who owns ARS Pharmaceuticals, Inc.
Who owns ARS Pharmaceuticals, Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of ARS Pharmaceuticals, Inc.: Ra Capital Management, L.P. (11.1%, Schedule 13D/A, filed 2025-10-01), Rubric Capital Management LP (8.06%, Schedule 13G/A, filed 2026-05-15), James E. Flynn (7.75%, Schedule 13D/A, filed 2025-08-01) and Blackrock, Inc. (5.3%, Schedule 13G, filed 2026-07-27).
Who are the largest shareholders of ARS Pharmaceuticals, Inc.?
By the share each holder's latest filing reports, the largest holders of ARS Pharmaceuticals, Inc. on this page are Ra Capital Management, L.P. (11.1%), Rubric Capital Management LP (8.06%) and James E. Flynn (7.75%).
When did Ra Capital Management, L.P. buy into ARS Pharmaceuticals, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Ra Capital Management, L.P. on this page is the Schedule 13D/A, filed 2025-10-01, reporting 11.1%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on ARS Pharmaceuticals, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on ARS Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on ARS Pharmaceuticals, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-07-17 | Richard Lowenthal | Director | departed | |
| Form 8-K, 2026-07-17 | Sarina Tanimoto | Chief Medical Officer | departed |
Which insiders own ARS Pharmaceuticals, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief medical officer and a 10% owner: 11,353,141 shares (11.3% of shares outstanding), held indirectly through a sarina tanimoto charitable remainder unitrust dated january 7, 2020 (Form 4, 2025-08-21).
- , the chief executive and president: 11,303,141 shares (11.2% of shares outstanding), held indirectly through a richard e. lowenthal charitable remainder unitrust dated january 7, 2020 (Form 4, 2025-08-22).
- Deerfield Private Design Fund III, L.P., a 10% owner: 9,774,508 shares (9.7% of shares outstanding), held indirectly through Through Deerfield Private Design Fund IV, L.P. and 1 other Through Deerfield fund, on a joint filing (Form 4, 2025-07-01).
- , L.P., a 10% owner: 9,774,508 shares (9.7% of shares outstanding), held indirectly through Through Deerfield Private Design Fund IV, L.P. and 1 other Through Deerfield fund, on a joint filing (Form 4, 2025-07-01).
- Deerfield Private Design Fund IV, L.P., a 10% owner: 9,774,508 shares (9.7% of shares outstanding), held indirectly through Through Deerfield Private Design Fund IV, L.P. and 1 other Through Deerfield fund, on a joint filing (Form 4, 2025-07-01).
Shares outstanding: 100,528,400 as of 2026-11-03, from the company's latest SEC cover page.
How much has ARS Pharmaceuticals, Inc. raised?
No fundraising or offering filing from ARS Pharmaceuticals, Inc. is on file with us.
Keep reading
More on ARS Pharmaceuticals, Inc. and the records around it.
ARS Pharmaceuticals, Inc. elsewhere on the record
- 5%+ stake filings Jul 2026
- Leadership changes Jul 2026
Companies that share a holder
- Deerfield Mgmt III, L.P. also filed stake reports on 19 other companies: Climb Bio, Inc. (Oct 2026), Cogent Biosciences, Inc. (Aug 2026), Enhabit, Inc. (Aug 2026)
- Rubric Capital Management LP also filed stake reports on 32 other companies: ARDELYX, INC. (Aug 2026), Enovis Corporation (Aug 2026), MeiraGTx Holdings plc (Aug 2026)
- RA Capital Management, L.P. also filed stake reports on 100 other companies: Climb Bio, Inc. (Nov 2026), Bambusa Therapeutics, Inc. (Nov 2026), SOLID BIOSCIENCES INC. (Nov 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/ars-pharmaceuticals